title: Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity.
abstract: The immunosuppressive management of liver transplant recipients suffering early calcineurin inhibitor-induced neurotoxicity is a challenge in daily clinical practice. We have assessed the use of everolimus as the main immunosuppressant in patients presenting severe neurotoxicity in the early post-transplantation period. From October 1988 to October 2012, 10 patients in our center received everolimus because of severe neurotoxicity in the 1st 3 months after transplantation. We analyzed several variables associated with this treatment, including patient characteristics, time from liver transplantation to conversion to everolimus, immunosuppression regimens before and after conversion, treatment efficacy, adverse events, and discontinuation after conversion. Median follow-up after conversion to everolimus was 27 months (range, 1-63 mo). Neurotoxic events were: akinetic mutism in 4 patients, repeated convulsions in 3, cerebrovascular accident in 1, Guillain-Barré syndrome in 1, and disabling tremor in 1. Treatment with calcineurin inhibitors was discontinued in all patients. Post-conversion regimens consisted of everolimus plus mycophenolate mofetil (MMF) plus steroids in 7 patients, everolimus plus MMF in 1, everolimus plus steroids in 1, and everolimus alone in 1. Liver function was maintained for ≥1 month in all patients except 1, who presented a severe rejection that was treated with steroid bolus and Neoral cyclosporine. Neurologic function was fully recovered in 8 patients. In 1 patient with akinetic mutism and another with convulsions, tacrolimus was reintroduced at 2 months and 1 month, respectively, after resolution of the neurotoxic event. Everolimus is feasible and effective as the main immunosuppressant in patients suffering severe neurotoxicity during the 1st 3 months after transplantation. It allows neurologic function to be recovered while maintaining adequate liver function.
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain. Electronic address: ibilbao@vhebron.net.
authors.forename: I
authors.initials: I
authors.lastname: Bilbao
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Dopazo
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Castells
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Lazaro
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Caralt
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Sapisochin
authors.affiliation: Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Charco
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000150:complications / Q000188:drug therapy*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology*; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D066027:Transplant Recipients; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus